Literature DB >> 30354710

Extracellular Ubiquitin(1-76) and Ubiquitin(1-74) Regulate Cardiac Fibroblast Proliferation.

Edwin K Jackson1, Eric Mi1, Vladimir B Ritov1, Delbert G Gillespie1.   

Abstract

SDF-1α (stromal cell-derived factor-1α) is a CXCR4-receptor agonist and DPP4 (dipeptidyl peptidase 4) substrate. SDF-1α, particularly when combined with sitagliptin to block the metabolism of SDF-1α by DPP4, stimulates proliferation of cardiac fibroblasts via the CXCR4 receptor; this effect is greater in cells from spontaneously hypertensive rats versus Wistar-Kyoto normotensive rats. Emerging evidence indicates that ubiquitin(1-76) exists in plasma and is a potent CXCR4-receptor agonist. Therefore, we hypothesized that ubiquitin(1-76), similar to SDF-1α, should increase proliferation of cardiac fibroblasts. Contrary to our working hypothesis, ubiquitin(1-76) did not stimulate cardiac fibroblast proliferation, yet unexpectedly antagonized the proproliferative effects of SDF-1α combined with sitagliptin. In this regard, ubiquitin(1-76) was more potent in spontaneously hypertensive versus Wistar-Kyoto cells. In the presence of 6bk (selective inhibitor of insulin-degrading enzyme [IDE]; an enzyme known to convert ubiquitin(1-76) to ubiquitin(1-74)), ubiquitin(1-76) no longer antagonized the proproliferative effects of SDF-1α/sitagliptin. Ubiquitin(1-74) also antagonized the proproliferative effects of SDF-1α/sitagliptin, and this effect of ubiquitin(1-74) was not blocked by 6bk and was >10-fold more potent compared with ubiquitin(1-76). Neither ubiquitin(1-76) nor ubiquitin(1-74) inhibited the proproliferative effects of the non-CXCR4 receptor agonist neuropeptide Y (activates Y1 receptors). Cardiac fibroblasts expressed IDE mRNA, protein, and activity and converted ubiquitin(1-76) to ubiquitin(1-74). Spontaneously hypertensive fibroblasts expressed greater IDE activity. Extracellular ubiquitin(1-76) blocks the proproliferative effects of SDF-1α/sitagliptin via its conversion by IDE to ubiquitin(1-74), a potent CXCR4 antagonist. Thus, IDE inhibitors, particularly when combined with DPP4 inhibitors or hypertension, could increase the risk of cardiac fibrosis.

Entities:  

Keywords:  CXCR4 receptor; SDF-1α; fibroblasts; hypertension; neuropeptide Y; ubiquitin

Mesh:

Substances:

Year:  2018        PMID: 30354710      PMCID: PMC6206878          DOI: 10.1161/HYPERTENSIONAHA.118.11666

Source DB:  PubMed          Journal:  Hypertension        ISSN: 0194-911X            Impact factor:   10.190


  27 in total

1.  Crucial role of stromal cell-derived factor-1alpha in neointima formation after vascular injury in apolipoprotein E-deficient mice.

Authors:  Andreas Schober; Sandra Knarren; Michael Lietz; Elisa A Lin; Christian Weber
Journal:  Circulation       Date:  2003-10-27       Impact factor: 29.690

Review 2.  Extracellular ubiquitin: immune modulator and endogenous opponent of damage-associated molecular pattern molecules.

Authors:  Matthias Majetschak
Journal:  J Leukoc Biol       Date:  2010-08-05       Impact factor: 4.962

3.  Isolation of a polypeptide that has lymphocyte-differentiating properties and is probably represented universally in living cells.

Authors:  G Goldstein; M Scheid; U Hammerling; D H Schlesinger; H D Niall; E A Boyse
Journal:  Proc Natl Acad Sci U S A       Date:  1975-01       Impact factor: 11.205

4.  Endomyocardial expression of SDF-1 predicts mortality in patients with suspected myocarditis.

Authors:  Christine S Zuern; Britta Walker; Martina Sauter; Malte Schaub; Madhumita Chatterjee; Karin Mueller; Dominik Rath; Sebastian Vogel; Roland Tegtmeyer; Peter Seizer; Tobias Geisler; Reinhard Kandolf; Florian Lang; Karin Klingel; Meinrad Gawaz; Oliver Borst
Journal:  Clin Res Cardiol       Date:  2015-05-26       Impact factor: 5.460

Review 5.  Ubiquitin-mediated protein degradation.

Authors:  A Hershko
Journal:  J Biol Chem       Date:  1988-10-25       Impact factor: 5.157

Review 6.  Context-dependent effects of dipeptidyl peptidase 4 inhibitors.

Authors:  Edwin K Jackson
Journal:  Curr Opin Nephrol Hypertens       Date:  2017-03       Impact factor: 2.894

7.  NPY1-36 and PYY1-36 activate cardiac fibroblasts: an effect enhanced by genetic hypertension and inhibition of dipeptidyl peptidase 4.

Authors:  Xiao Zhu; Delbert G Gillespie; Edwin K Jackson
Journal:  Am J Physiol Heart Circ Physiol       Date:  2015-09-14       Impact factor: 4.733

8.  Inhibition of renal dipeptidyl peptidase IV enhances peptide YY1-36-induced potentiation of angiotensin II-mediated renal vasoconstriction in spontaneously hypertensive rats.

Authors:  Edwin K Jackson; Mingdi Zhang; Weili Liu; Zaichuan Mi
Journal:  J Pharmacol Exp Ther       Date:  2007-08-28       Impact factor: 4.030

9.  Role of RACK1 in the differential proliferative effects of neuropeptide Y(1-36) and peptide YY(1-36) in SHR vs. WKY preglomerular vascular smooth muscle cells.

Authors:  Dongmei Cheng; Xiao Zhu; Delbert G Gillespie; Edwin K Jackson
Journal:  Am J Physiol Renal Physiol       Date:  2013-01-09

10.  CXCR4 Antagonism Attenuates the Development of Diabetic Cardiac Fibrosis.

Authors:  Po-Yin Chu; Ken Walder; Duncan Horlock; David Williams; Erin Nelson; Melissa Byrne; Karin Jandeleit-Dahm; Paul Zimmet; David M Kaye
Journal:  PLoS One       Date:  2015-07-27       Impact factor: 3.240

View more
  3 in total

Review 1.  Cardioprotective Potential of Exogenous Ubiquitin.

Authors:  Suman Dalal; Paige L Shook; Mahipal Singh; Krishna Singh
Journal:  Cardiovasc Drugs Ther       Date:  2020-09-10       Impact factor: 3.947

2.  CXCR4 Antagonism Reduces Cardiac Fibrosis and Improves Cardiac Performance in Dilated Cardiomyopathy.

Authors:  Po-Yin Chu; Mandar S Joshi; Duncan Horlock; Helen Kiriazis; David M Kaye
Journal:  Front Pharmacol       Date:  2019-02-19       Impact factor: 5.810

3.  Natural and engineered chemokine (C-X-C motif) receptor 4 agonists prevent acute respiratory distress syndrome after lung ischemia-reperfusion injury and hemorrhage.

Authors:  Favin S Babu; Xiaomei Liang; Garrett A Enten; Anthony J DeSantis; Brian F Volkman; Xianlong Gao; Matthias Majetschak
Journal:  Sci Rep       Date:  2020-07-09       Impact factor: 4.379

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.